Navigation Links
Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
Date:12/1/2011

PITTSBURGH, Dec. 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today affirmed its commitment to expand the access of people living with HIV/AIDS in the developing world to high quality, affordable treatment. The company is the proud sponsor of a special World AIDS Day exhibition and reception today in Washington D.C. The event is hosted by the World AIDS Institute in cooperation with the Congressional HIV/AIDS Caucus.

Mylan President Heather Bresch said: "As a company dedicated to meeting unmet needs, we honor on this 23rd World AIDS Day those who have died from HIV/AIDS and those living with the disease, including the nearly 10 million people worldwide who are in immediate need of treatment and care. Everyone living with HIV/AIDS deserves to have access to affordable treatment, and we intend to do our part to help them obtain it."

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), about 33 million people currently are infected with HIV. Approximately 85% of these individuals live in sub-Saharan Africa. According to the World Health Organization's (WHO) treatment guidelines, 15 million of those infected need treatment, but only 6.6 million, or less than half of them, receive it.

New research suggests that improved access to antiretroviral (ARV) treatment may be the most effective means to prevent HIV transmission.

Mylan's efforts reflect this research. In addition to providing affordable high-quality ARV products, the company is advocating that treatment begin soon after diagnosis to ensure better health outcomes for individuals, reduce HIV transmission and create long-term cost savings. Mylan also is encouraging the expansion of HIV testing programs, as they are a prerequisite for treatment. In addition, the company supports efforts to reform how programs are funded and services are delivered so as to use existing resources more efficiently and improve accountability for results.

Mylan also remains highly committed to partnering with members of the global community, including governments, non-governmental organizations and the private sector, to implement new and innovative practices and achieve the goal of universal access established by the United Nations.

Bresch continued: "Not only will expanding access to ARVs save the lives of millions living with HIV/AIDS, it will dramatically reduce transmission of the HIV virus. By taking bold action now, members of the global community can unite to help ensure the eventual eradication of this devastating disease."

Mylan has helped fuel a steep decline in ARV drug costs over the last decade. As recently as 2000, the cost to supply one person living with HIV/AIDS with a year's supply of ARV medicine averaged about $10,000. In 2008, low-income countries paid, on average, $400 per patient per year for a WHO-recommended once-daily regimen. And prices have continued to drop even further, as that same regimen now is available for $159 per patient per year, a reduction of 60 percent since 2008 alone.

Mylan has also delivered important innovations for the patients who rely on its products, including a heat-stable ARV product that can be distributed and used in warm climates where refrigeration infrastructure is not widely available, and advances in packaging that make it easier for people to adhere to their treatment plans. Additionally, Mylan's is currently the only FDA-approved generic triple combination, once-a-day ARV with Tenofovir, which is recommended by WHO as a first-line treatment. Mylan's ARV products are helping approximately one-third of all people receiving treatment today for HIV/AIDS in the developing world.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 2016 , ... US Sports Camps is proud to sponsor the Bay Area ... top non-profit leaders, ultimate organizations, and coaches from around the US. The theme for ... Program Director of Youth and Education, describes this year YUCC as “an important conversation ...
Breaking Medicine News(10 mins):